Ventrus shares slump after anal fissure drug fails in trial

[riky]

Ventrus shares slump after anal fissure drug fails in trial

(Reuters) - Ventrus Biosciences Inc's shares plunged 66 percent after the company said its lead experimental treatment for anal fissures failed to reduce pain compared with a placebo in a second late-stage trial. (http://link.reuters.com/xuw76v) Ventrus said on Wednesday it planned to request for a meeting with the U.S. Food and Drug Administration to determine the next steps in submitting a new drug application (NDA). "We think Ventrus will still submit the NDA for a 12-month review cycle sometime in the third quarter of 2014, which would set it up for a (review date) in mid-2015...we continue to model (its) launch in mid-late 2015", Cantor Fitzergald analyst Irina Rivkind wrote in a note. The treatment could compete with Rectiv, marketed by Aptalis Pharmaceuticals Inc. Forest Laboratories Inc said in January it would buy Aptalis.

Source: You are not allowed to view links. Register or Login